APOA2

Across TCGA pan-cancer cohorts, APOA2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated APOA2 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APOA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APOA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where APOA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.887	0.540	.002	26	view →
COAD	DFS	Median	II,III,IV	0.880	1.000	.020	24	view →
HNSC	DFS	Median	III,IV	0.870	0.702	.031	16	view →
LUAD	OS	Quartile	II,III,IV	0.339	0.843	.002	15	view →
GBM	DFS	Tertile	All	0.519	0.204	.005	12	view →
PDAC	OS	Tertile	All	0.374	0.688	.012	11	view →
LSCC	OS	Quartile	All	0.927	0.857	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

APOA2–CCRCC (DFS)

Open the CCRCC breakdown →